Literature DB >> 19464104

Hepatitis B virus X gene is implicated in liver carcinogenesis.

Katsuro Koike1.   

Abstract

Hepatitis B virus (HBV) is a small hepatotropic and highly species-specific enveloped DNA virus. The carcinogenicity of this virus has become focused on the X gene and its coded X protein. The X protein itself is unable to bind to DNA directly, but works as a potent transcriptional activator through multiple cis-acting elements and mediates several signal transduction cascades. Two regions of the X protein, aa.61-69 and aa.105-140, are found essential for the viral replication and expression as well. These functions interacting with transcription factors and signaling cascades are acting cooperatively to cause cell proliferation. Furthermore, the association of X protein with mitochondria causes loss of the mitochondrial membrane potential and subsequently causes cell death, the function of which is attributed to the aa.68-104 region of X protein. As a result, the X protein has two independent proliferative and cell death-promoting activities. Liver cancer has been shown to result from a series of mutations in specific oncogenes and tumor suppressor genes. In a recent study, X protein stimulates ROS generation in the mitochondria due to collapse of the membrane potential and increases the mutation frequency, that evokes malignant transformation. Inflammation as a result of HBV infection is concerned to cause DNA damage. In the past 10years, the possibility that several viral proteins directly engaged in the DNA damage has increased to some extent. From an evolutionary viewpoint, it is noteworthy that several arrangement proteins have been found in viruses. Thus, there is some clue that a small amount of X protein acts as an arrangement protein for HBV replication dependent upon cellular DNA damage due to generated ROS as an amplified signal.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464104     DOI: 10.1016/j.canlet.2009.04.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

1.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 2.  Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.

Authors:  Amir Shlomai; Ype P de Jong; Charles M Rice
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

3.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress.

Authors:  Vonetta M Williams; Maria Filippova; Ubaldo Soto; Penelope J Duerksen-Hughes
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

4.  Functional implications of mitochondrial reactive oxygen species generated by oncogenic viruses.

Authors:  Young Bong Choi; Edward William Harhaj
Journal:  Front Biol (Beijing)       Date:  2014-12

5.  Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses.

Authors:  D Ivacik; A Ely; N Ferry; P Arbuthnot
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

6.  Hepatitis B virus X protein promotes hepatoma cell proliferation via upregulation of MEKK2.

Authors:  Guang-yao Kong; Jun-ping Zhang; Shuai Zhang; Chang-liang Shan; Li-hong Ye; Xiao-dong Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-08-01       Impact factor: 6.150

Review 7.  Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges.

Authors:  Michael J Bouchard; Sonia Navas-Martin
Journal:  Cancer Lett       Date:  2010-12-18       Impact factor: 8.679

8.  Cancer as a metabolic disease.

Authors:  Thomas N Seyfried; Laura M Shelton
Journal:  Nutr Metab (Lond)       Date:  2010-01-27       Impact factor: 4.169

Review 9.  Perspectives on the mesenchymal origin of metastatic cancer.

Authors:  Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

10.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Fang Xu; Xiaohao Shi; Yue Wang; Linhong Deng
Journal:  Cytotechnology       Date:  2014-07-08       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.